A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy-Reference-Cited by-同舟云学术

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

Published:2014-02-27 Issue:11 Volume:120 Page:1647-1655
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Garcia Jorge A.¹,Hudes Gary R.²,Choueiri Toni K.³,Stadler Walter M.⁴,Wood Laura S.¹,Gurtler Jayne⁵,Bhatia Shailender⁶⁷,Joshi Adarsh⁸,Hozak Rebecca R.⁸,Xu Yihuan⁹,Schwartz Jonathan D.⁹,Thompson John A.⁶⁷

Affiliation:

1. Cleveland Clinic Taussig Cancer Institute; Cleveland Ohio

2. Department of Medical Oncology; Fox Chase Cancer Center; Philadelphia Pennsylvania

3. Dana-Farber Cancer Institute/Harvard Medical School; Boston Massachusetts

4. Hematology/Oncology Section; The University of Chicago; Chicago Illinois

5. Metarie Oncology; Metairie Louisiana

6. Seattle Cancer Care Alliance; Seattle Washington

7. Fred Hutchinson Cancer Research Center; University of Washington; Seattle Washington

8. Eli Lilly and Company; Indianapolis Indiana

9. ImClone Systems Inc.; Branchburg New Jersey

Publisher

Wiley